Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication.
about
Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemiaLestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside.Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia.Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology GroupFLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML.Lestaurtinib enhances the antitumor efficacy of chemotherapy in murine xenograft models of neuroblastoma
P2860
Acute myeloid leukaemia blast cells with a tyrosine kinase domain mutation of FLT3 are less sensitive to lestaurtinib than those with a FLT3 internal tandem duplication.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Acute myeloid leukaemia blast ...... 3 internal tandem duplication.
@en
Acute myeloid leukaemia blast ...... 3 internal tandem duplication.
@nl
type
label
Acute myeloid leukaemia blast ...... 3 internal tandem duplication.
@en
Acute myeloid leukaemia blast ...... 3 internal tandem duplication.
@nl
prefLabel
Acute myeloid leukaemia blast ...... 3 internal tandem duplication.
@en
Acute myeloid leukaemia blast ...... 3 internal tandem duplication.
@nl
P2093
P2860
P1476
Acute myeloid leukaemia blast ...... 3 internal tandem duplication.
@en
P2093
Asim Khwaja
David C Linch
Panagiotis D Kottaridis
Rosemary E Gale
Satomi Matsuda
P2860
P304
P356
10.1111/J.1365-2141.2008.07025.X
P407
P50
P577
2008-03-12T00:00:00Z